Neoadjuvant Chemotherapy Shows Promise for Resectable Colon Cancer

Neoadjuvant chemotherapy may enhance surgical outcomes for locally advanced resectable colon cancer, but careful patient selection is crucial.

Foxtrot trial showed reduced 2-year residual or recurrent disease (16.9% vs. 21.5%; p=0.037) and higher complete resection rates with fewer complications.
Optical trial indicated improved overall survival (HR 0.44; p=0.002), though disease-free survival was not statistically significant.

Surgical teams should consider neoadjuvant therapy to improve resection rates and long-term outcomes in select patients.

Meta-analysis supported better recurrence and survival rates without increased surgical risk.

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

More in Intestine and Lower Gastrointestinal Tract

Ann Surg Oncol2 Nov 2026

Patients smoking at diagnosis were less likely to have a favorable response to treatment before rectal cancer surgery; former smokers were not.

JAMA Surg30 Oct 2026

For severe slow-transit constipation, removing less colon gave similar symptom relief at one year, with less early incontinence.

Surg Endosc29 Oct 2026

In low rectal cancer surgery, removing the specimen through the anus was linked to fewer wound complications and less pain in the first two days.